Spain: Vifor Pharma to acquire Sanifit for upfront €205m to further strengthen late-stage pipeline in nephrology

Switzerland headquartered and SIX Swiss Exchange listed global pharmaceuticals company, Vifor Pharma is to acquire Spanish clinical-stage cardio-renal biopharmaceutical company Sanifit. Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, whose shareholders will receive an upfront payment of €205m. There are also clinical, regulatory and market access milestones that could add up…

You must be a HMI Subscriber to view this content.

Subscribe Now »